Partial
Mostly Aligned
Patient Risk:
Low
Summary
Most mechanistic and descriptive claims align with the provided label excerpts (description and mechanism). However, the indication language is incomplete/partially verifiable due to missing label text, and one dosing/timing claim (taken with meals) cannot be confirmed from the provided sections. No evaluation of critical safety domains is possible from the supplied excerpts.
Category Scores
Accurate Statements
Auryxia is the brand name for ferric citrate.
11 DESCRIPTION: "Auryxia (ferric citrate)"
Auryxia is a phosphate binder.
11 DESCRIPTION: "Auryxia (ferric citrate), a phosphate binder"
Auryxia binds dietary phosphate in the gut so less phosphate is absorbed into the bloodstream.
12.1 Mechanism of Action: "Ferric iron binds dietary phosphate in the GI tract... By binding phosphate in the GI tract and decreasing absorption..."
Ferric citrate, as a phosphate binder, binds phosphate from food during digestion in the digestive tract.
12.1 Mechanism of Action: "Ferric iron binds dietary phosphate in the GI tract"
Unsupported Statements
Auryxia is used to help treat phosphate levels in people with chronic kidney disease (CKD).
Only partially supported because the provided excerpt for 1 INDICATIONS AND USAGE is missing; the mechanism excerpt refers to "Hyperphosphatemia in Chronic Kidney Disease on Dialysis" but the claim is broader (no dialysis/non-dialysis specification).
Lower phosphate absorption helps reduce hyperphosphatemia in advanced CKD.
Partially supported. The provided mechanism language is specific to "Hyperphosphatemia in Chronic Kidney Disease on Dialysis," while the claim uses a broader "advanced CKD" description not verifiable from the provided excerpts.
Auryxia is generally taken with meals.
Cannot be confirmed: section 2 DOSAGE AND ADMINISTRATION text is not provided in the available excerpts, so meal-timing instructions are not verifiable.
Contradictions
Important Omissions
No assessment of contraindications, boxed warnings, warnings/precautions, drug interactions, adverse reactions, monitoring recommendations, or detailed dosing/administration safety was possible because the provided label excerpts do not include these sections.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The supported statements concern identity and mechanism of phosphate binding. However, at least one administration/timing claim cannot be verified from the provided label excerpts, and overall safety domain compliance cannot be determined due to missing label content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Incomplete/insufficient label excerpting for indication wording and administration (meal timing), and no ability to evaluate critical safety content.
Suggested Improvement
Limit claims to what is explicitly supported by the provided label excerpts (e.g., mechanism and identity) and avoid/unverify dosing timing (e.g., with meals) unless section 2 text is provided. Provide full label sections (1 and 2, plus boxed warnings/safety content) for comprehensive on-label compliance checking.